Xenetic Biosciences, Inc. (XBIO)

$3.2897

+0.03 (+0.91%)
Rating:
Recommendation:
Buy
Symbol XBIO
Price $3.2897
Beta 2.772
Volume Avg. 0.02M
Market Cap 4.989M
Shares () -
52 Week Range 2.4-10.0
1y Target Est -
DCF Unlevered XBIO DCF ->
DCF Levered XBIO LDCF ->
ROE -71.79% Strong Sell
ROA -73.49% Strong Sell
Operating Margin -
Debt / Equity 7.86% Neutral
P/E -0.80
P/B 0.34 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest XBIO news


Mr. Jeffrey F. Eisenberg Esq.
Healthcare
Biotechnology
NASDAQ Capital Market

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.